Trials / Recruiting
RecruitingNCT06754930
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
A Multicenter, Open Phase IB/II Clinical Study of Safety, Tolerability, and Efficacy of SHR-1826 in Combination With Other Anti-cancer Treatment in Patients With Non-small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1826 | SHR-1826 for injection. |
| DRUG | SHR-1316 | SHR-1316 for injection. |
| DRUG | SHR-9839 | SHR-9839 for injection. |
| DRUG | SHR-8068 | SHR-8068 for injection. |
| DRUG | Ametinib mesylate | Ametinib mesylate. |
| DRUG | BP-102 | BP-102 for injection. |
| DRUG | Carboplatin | Carboplatin for injection. |
Timeline
- Start date
- 2025-02-18
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2025-01-01
- Last updated
- 2025-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06754930. Inclusion in this directory is not an endorsement.